Navigation Links
First Duplex Test for Parvovirus B19 and Hepatitis A Virus Now Available in the US

PLEASANTON, Calif., Feb. 4, 2011 /PRNewswire/ -- Roche (SIX: RO, ROG; Pink Sheets: RHHBY) announced today that the cobas® TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A virus (HAV) simultaneously in one assay in human plasma.

Human plasma is used to create treatments for life-threatening and chronic diseases and disorders such as hemophilia and primary immunodeficiency diseases. Plasma is also used to treat patients who have suffered severe burns or trauma and has many other therapeutic uses.

"The launch of this test is an important part of our strategy," said Paul Brown, Head of Roche Molecular Diagnostics, "not only is it an important test for the continued safety of plasma products, but it also indicates our continued commitment to this vital area."

The test is a state-of-the-art, in vitro nucleic acid amplification technology (NAT) test which offers complete coverage of all human genotypes of parvovirus B19 (genotypes 1, 2 and 3 DNA) and HAV (genotypes I, II and III RNA) in human plasma.

The cobas® TaqScreen DPX Test uses multi-dye, real-time polymerase chain reaction (PCR) technology which allows for the simultaneous detection and identification of individual viral targets without the use of additional discriminatory tests. A further innovative aspect of this test is that facilitates quantification of the parvovirus B19 while detecting extremely low levels of HAV.

Both parvovirus B19 and HAV are difficult to inactivate by traditional methods used by the plasma industry and there have been reports on the transmission of HAV and parvovirus B19 through blood and plasma products. Both parvovirus B19 and HAV in human plasma can be detected by NAT during the manufacturing process of plasma products, so improving the safety of these products.

About Roche Blood and Plasma Screening Roche is a leader in the global NAT blood and plasma screening market, which is estimated at almost 900 million CHF. Nucleic acid-based tests enable earlier detection of active viral infections than conventional antibody or antigen assays. Roche's real-time PCR-based nucleic acid assays have been used since 1998 to screen blood and plasma products. Currently, more than 225 blood banks worldwide use Roche's automated cobas s 201 system.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.

Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

All trademarks used or mentioned in this release are legally protected by law.

(1) The cobas® TaqScreen DPX Test is not an FDA-licensed product.

For further information please contact: Marianne van ZeelandRoche Molecular Diagnostics Communications+1 925-549-1232 (Mobile)

SOURCE Roche Molecular Systems
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. First National Amniotic Fluid Awareness Day Educates Women About the Benefits of Amniotic Fluid Beyond Pregnancy
2. Cellectis bioresearch First to Launch Revolutionary Custom TAL Nuclease Service
3. Waters New Biopharmaceutical System Solution Uniquely Unites UPLC/MS Analyses and Workflows Driven by Industry First Scientific Information System
4. Pittsburgh Life Sciences Greenhouse Announces the First Close of the PLSG Accelerator Fund LLC at $5 Million
5. Texas A&M professor helps develop first high-temp spin-field-effect transistor
6. El Camino Hospital Announces First Implant in Clinical Trial to Evaluate Revolutionary Heart Valve Procedure
7. Teysuno™ (S-1) Receives CHMP Positive Opinion for Approval as First-Line Therapy for Advanced Gastric Cancer
8. Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
9. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
10. Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System
11. Sigma® Life Science Creates Worlds First Knock-in Rats using Zinc Finger Nuclease Technology
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Vancouver ... lancet that features Owen Mumford,s unique Comfort Zone Technology®. ... Unistik® Touch is a touch activated lancet that features ... Owen Mumford, a leading medical device manufacturer, today unveils ... available initially in the US before expanding out to ...
(Date:12/1/2015)... Dec. 1, 2015 Today the Allen Institute ... Seattle,s South Lake Union neighborhood, the ... Mercer Street and Westlake Avenue North, the 270,000 square ... Institute for Brain Science and the Allen Institute for ... and founder of the Allen Institute. "We started by ...
(Date:12/1/2015)... CAMBRIDGE, Mass. , Dec. 1, 2015 ... and the McGovern Institute for Brain Research at MIT ... system that significantly cut down on "off-target" editing errors. ... issues in the use of genome editing. ... report that changing three of the approximately 1,400 amino ...
(Date:12/1/2015)... -- Twist Bioscience, a company focused on synthetic DNA, today announced ... selected as one of Foreign Policy,s 100 Leading ... of life . Each year, Foreign Policy selects ... have changed lives and are shaping the world. ... to be recognized among these incredible global leaders," said Leproust. ...
Breaking Biology Technology:
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):